Research Areas

Dr. Lok’s research includes studies on the natural history and treatment of chronic hepatitis B and C, and prevention and treatment of recurrent hepatitis B and C after liver transplantation.

Study Projects

• Prevention of recurrent hepatitis B after liver transplantation

• HBV recurrence rate and factors associated with recurrence
• Outcomes of liver transplant patients with hepatitis B

• Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial

• Hepatocellular carcinoma – incidence, associating factors, predictive models, and biomarkers
• Hepatic steatosis and liver disease progression

• Adult-to-adult liver transplantation

• Outcomes of patients transplanted for hepatitis C and efficacy of pre-transplant antiviral therapy

• Antiviral drug-resistant HBV mutations: incidence and response to rescue therapies

• Hepatitis B patients with normal liver enzymes: liver histology and outcomes

•Eltrombopag in hepatitis C patients with thrombocytopenia, to enable initiation of peginterferon and ribavirin therapy

•New tratments for hepatitis B and C

Selected Publications

1. Tan J, Degertekin B, Wong SN, Hussain M, Oberhelman K, Lok ASF. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir
   in the absence of adefovir-resistant mutations. Journal of Hepatology 48: 391-8, 2008.
2. DiBisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL for the HALT-C Trial Group. Prolonged therapy of advanced chronic hepatitis C with low dose peginterferon. NEJM 359: 2429-41, 2008.
3. Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL,Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD, and the HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136: 138-148, 2009.
4. Degertekin B, Hussain M, Tan J, Oberhelman K, Lok AS. Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. Journal of Hepatology 50: 42-8, 2009.
5. Lok ASF, McMahon BJ. AASLD Practice Guidelines: Hepatitis B. Hepatology 45:507-539, 2007.
6. Degertekin B and Lok ASF. Indications for therapy in hepatitis B. Hepatology 49: S129-137, 2009 .

Honors/Awards
2008    Hepatitis B Foundation, Distinguished Scientist Award
2008    American Gastroenterological Association Foundation, Outstanding Women in Science
2008    Alice Lohrman Andrews Research Professorship

Patient Information

Clinic address:
Liver Clinic
3326 Taubman Center
3rd floor, Reception Area D
1500 East Medical Center Drive
Ann Arbor, MI 48109

Appointments:
800-395-6431
734-936-0499
Fax: 734-763-4574

Nurses:
734-936-0499
Fax: 734-763-4574


Academic Information

Office address:
UMHS, Department of Internal Medicine
Division of Gastroenterology
3912 Taubman Center, SPC 5362
1500 East Medical Center Drive
Ann Arbor, MI 48109
734-936-7511
Fax: 734-936-7392